CN115803032A - Sting激动剂与免疫检查点抑制剂的联合治疗 - Google Patents

Sting激动剂与免疫检查点抑制剂的联合治疗 Download PDF

Info

Publication number
CN115803032A
CN115803032A CN202180046447.0A CN202180046447A CN115803032A CN 115803032 A CN115803032 A CN 115803032A CN 202180046447 A CN202180046447 A CN 202180046447A CN 115803032 A CN115803032 A CN 115803032A
Authority
CN
China
Prior art keywords
inhibitor
sting agonist
administered
patient
ctla4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180046447.0A
Other languages
English (en)
Chinese (zh)
Inventor
陈志坚
孙立军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunosensor Therapy Co ltd
The University of Texas System
Original Assignee
Immunosensor Therapy Co ltd
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunosensor Therapy Co ltd, The University of Texas System filed Critical Immunosensor Therapy Co ltd
Publication of CN115803032A publication Critical patent/CN115803032A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202180046447.0A 2020-05-15 2021-05-17 Sting激动剂与免疫检查点抑制剂的联合治疗 Pending CN115803032A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063025905P 2020-05-15 2020-05-15
US63/025,905 2020-05-15
US202063091874P 2020-10-14 2020-10-14
US63/091,874 2020-10-14
PCT/US2021/032800 WO2021232019A1 (en) 2020-05-15 2021-05-17 Sting agonist combination treatments with immune checkpoint inhibitors

Publications (1)

Publication Number Publication Date
CN115803032A true CN115803032A (zh) 2023-03-14

Family

ID=76306053

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180046447.0A Pending CN115803032A (zh) 2020-05-15 2021-05-17 Sting激动剂与免疫检查点抑制剂的联合治疗

Country Status (10)

Country Link
US (1) US20210380695A1 (cg-RX-API-DMAC10.html)
EP (1) EP4149457A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023533111A (cg-RX-API-DMAC10.html)
KR (1) KR20230011324A (cg-RX-API-DMAC10.html)
CN (1) CN115803032A (cg-RX-API-DMAC10.html)
AU (1) AU2021273508A1 (cg-RX-API-DMAC10.html)
CA (1) CA3178464A1 (cg-RX-API-DMAC10.html)
IL (1) IL298148A (cg-RX-API-DMAC10.html)
MX (1) MX2022014110A (cg-RX-API-DMAC10.html)
WO (1) WO2021232019A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114940679B (zh) * 2022-05-23 2023-05-16 浙江大学医学院附属第四医院 Sting激动剂前药化合物及其制备方法和应用
WO2024064724A1 (en) * 2022-09-21 2024-03-28 The University Of North Carolina At Chapel Hill Compositions and methods for treating cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107735103A (zh) * 2015-02-25 2018-02-23 纪念斯隆-凯特琳癌症中心 使用灭活的非复制型的修饰的痘苗病毒安卡拉(mva)作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂的组合
CN109475570A (zh) * 2016-03-18 2019-03-15 免疫传感器公司 环二核苷酸化合物及使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2935257T3 (es) 2013-03-15 2023-03-03 Univ Chicago Métodos y composiciones relacionadas con la actividad de las células T
JP2016524593A (ja) 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
EP2996472B1 (en) 2013-05-18 2019-03-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
CN103908468B (zh) 2014-04-21 2017-02-08 上海捌加壹医药科技有限公司 环二核苷酸cGAMP在制备抗肿瘤药物中的应用
DK3233882T3 (da) 2014-12-16 2020-01-27 Kayla Therapeutics Fluorinerede cykliske dinukleotider til cytokininduktion
CN108137641B (zh) 2015-08-13 2022-04-01 默沙东公司 作为sting激动剂的环状双核苷酸化合物
US20170158772A1 (en) 2015-12-07 2017-06-08 Opi Vi - Ip Holdco Llc Compositions of antibody construct - agonist conjugates and methods of use thereof
DE212016000029U1 (de) 2015-12-07 2017-07-30 Opi Vi - Ip Holdco Llc Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten
RU2019122598A (ru) 2016-12-20 2021-01-22 Мерк Шарп И Доум Корп. Циклические динуклеотидные агонисты sting для лечения рака
WO2018118664A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
CA3049791A1 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
EP3675859A4 (en) 2017-08-31 2021-06-30 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES
EP3755331B1 (en) 2018-02-21 2026-01-28 The Scripps Research Institute Agonists of stimulator of interferon genes (sting) for use in the treatment of cancer
JP2023500045A (ja) * 2019-10-14 2023-01-04 イミューンセンサー セラピューティクス、インコーポレイテッド Stingアゴニストを用いたがんを処置する方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107735103A (zh) * 2015-02-25 2018-02-23 纪念斯隆-凯特琳癌症中心 使用灭活的非复制型的修饰的痘苗病毒安卡拉(mva)作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂的组合
CN109475570A (zh) * 2016-03-18 2019-03-15 免疫传感器公司 环二核苷酸化合物及使用方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANPING LI 等: "Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy", 《JOURNAL OF HEMATOLOGY & ONCOLOGY》, 31 December 2019 (2019-12-31), pages 1 - 2 *
CASEY R. AGER 等: "Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity", 《CANCER IMMUNOL RES》, vol. 5, no. 8, 31 August 2017 (2017-08-31), pages 676 - 684, XP055825695, DOI: 10.1158/2326-6066.CIR-17-0049 *
STEPHANIE DORTA-ESTREMERA 等: "Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti- PD-1 immunotherapy in preclinical model of HPV+ oral cancer", 《JJOURNAL FOR IMMUNO THERAPY OF CANCER》, 31 December 2019 (2019-12-31), pages 1 - 12, XP093007194, DOI: 10.1186/s40425-019-0728-4 *

Also Published As

Publication number Publication date
KR20230011324A (ko) 2023-01-20
IL298148A (en) 2023-01-01
MX2022014110A (es) 2023-01-30
EP4149457A1 (en) 2023-03-22
JP2023533111A (ja) 2023-08-02
US20210380695A1 (en) 2021-12-09
AU2021273508A1 (en) 2022-12-15
WO2021232019A1 (en) 2021-11-18
CA3178464A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
Andrikopoulou et al. Trastuzumab deruxtecan (DS-8201a): the latest research and advances in breast cancer
WO2025061140A1 (zh) 治疗非霍奇金淋巴瘤的药物组合及其用途
US20210380695A1 (en) Sting agonist combination treatments with immune checkpoint inhibitors
BR112020009363A2 (pt) métodos e composições para tratar câncer por modificação de múltiplos braços do sistema imunológico
US20230121320A1 (en) Sting agonist combination treatments with cytokines
US20230270773A1 (en) Methods of treating cancer with a sting agonist
HK40087098A (en) Sting agonist combination treatments with immune checkpoint inhibitors
AU2005266106B2 (en) Combination anticancer therapy and pharmaceutical compositions therefore
CN120390655A (zh) 抗cd20抗体药物偶联物在制备治疗非霍奇金淋巴瘤的药物中的用途
US12240904B2 (en) Use of anti-PD-1 antibody in combination with famitinib in preparation of drug for treating tumors
HK40076423A (en) Methods of treating cancer with a sting agonist
EP4506015A1 (en) Combination of a mps1 inhibitor and an antibody drug conjugate
Karmali et al. Combinatorial treatment with carboxyamidotriazole-orotate and temozolomide in sc-implanted human LOX IMVI melanoma xenografts
WO2025261276A1 (zh) 含抗cd20抗体药物偶联物的药物组合及其治疗非霍奇金淋巴瘤的用途
IL316289A (en) Methods and compositions for treating diseases and disorders driven by eosinophils
RU2024114358A (ru) Способы лечения рака комбинацией антитела против pd-1 и конъюгата антитела против cd30-лекарственного средства
HK1255299B (en) Use of combination of anti-pd-1 antibody and vegfr inhibitor in preparation of drug for treating cancers
HK1255299A1 (en) Use of combination of anti-pd-1 antibody and vegfr inhibitor in preparation of drug for treating cancers

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40087098

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230314